HER2+ advanced gastric cancer: Current state and opportunities (Review)

被引：12

作者：

Hu, Hui-Hui ^{[1
,2
]}

Wang, Sai-Qi ^{[1
,2
]}

Zhao, Huichen ^{[3
]}

Chen, Zhe-Sheng ^{[4
]}

Shi, Xiaojing ^{[5
,8
]}

Chen, Xiao-Bing ^{[1
,2
,6
,7
]}

机构：

[1] Zhengzhou Univ, Affiliated Canc Hosp, Henan Engn Res Ctr Precis Therapy Gastrointestinal, Zhengzhou Key Lab PrecisTherapy Gastrointestinal C, Zhengzhou 450008, Henan, Peoples R China

[2] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China

[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Oncol, Xian 710061, Shaanxi, Peoples R China

[4] St Johns Univ, Coll Pharm & Hlth Sci, Queens, NY 11439 USA

[5] Zhengzhou Univ, Acad Med Sci, Zhengzhou 450052, Henan, Peoples R China

[6] Zhengzhou Univ, Affiliated Canc Hosp, Henan Engn Res Ctr Precis Therapy Gastrointestinal, Zhengzhou Key Lab Precis Therapy Gastrointestinal, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China

[7] Henan Canc Hosp, 127 Dong Ming Rd, Zhengzhou 450008, Henan, Peoples R China

[8] Zhengzhou Univ, Acad Med Sci, 40 Daxue north Rd, Zhengzhou 450052, Henan, Peoples R China

来源：

INTERNATIONAL JOURNAL OF ONCOLOGY | 2024年 / 64卷 / 04期

基金：

中国国家自然科学基金;

关键词：

advanced gastric cancer; human epidermal growth factor receptor 2; targeted therapy; immunotherapy; trastuzumab; HER2-TARGETED BISPECIFIC ANTIBODY; TYROSINE KINASE INHIBITOR; BREAST-CANCER; OPEN-LABEL; GASTROESOPHAGEAL JUNCTION; TRASTUZUMAB EMTANSINE; THERAPEUTIC TARGET; ANTITUMOR EFFICACY; PRELIMINARY SAFETY; PLUS OXALIPLATIN;

D O I：

10.3892/ijo.2024.5624

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Human epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10-20% of all cases of GC. Although the development of the anti-HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS-8201 and RC48 have been applied in the treatment of HER2+ AGC, and several novel anti-HER2 therapies are undergoing preclinical/clinical trials. At present, combination immunotherapy with anti-HER2 agents is used as the first-line treatment of this disease subtype. New promising approaches such as chimeric antigen receptor T-cell immunotherapy and cancer vaccines are also being investigated for their potential to improve clinical outcomes. The current review provides new insights that will guide the future application of anti-HER2 therapy by summarizing research progress on targeted therapy drugs for HER2+ AGC and combination treatments.

引用

页数：17

共 159 条

[51] Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review [J].